As evidenced that TME in IDH1mt-glioma patients in the high-risk score group can induce the inactivation of M1 cells and CD8 T cells, we furthered analyzed whether ICB had a high benefit for IDH1mt-glioma patients in the high-risk score group. This evidence concerns the gene CD8A and glioma.